News & Updates
Filter by Specialty:
Expectant mums’ use of dolutegravir safe for babies
Treatment with dolutegravir during pregnancy does not appear to pose an excess risk of adverse birth outcomes, according to two studies presented at the 24th International AIDS Conference in Montreal, Canada.
Expectant mums’ use of dolutegravir safe for babies
04 Aug 2022
Conversion to resectability uncommon in trials of unresectable mCRC patients
In clinical trials of patients with unresectable metastatic colorectal cancer (mCRC), conversion to resectability (C2R) rarely happens, reveals a study.
Conversion to resectability uncommon in trials of unresectable mCRC patients
04 Aug 2022
Abiraterone-olaparib confers clinical benefit for mCRPC patients
The combination of abiraterone and olaparib conferred significant improvement in radiographic progression-free survival (rPFS) in the first-line treatment of metastatic castration-resistant prostate cancer (mCRPC), according to findings from the phase III PROpel trial presented at EAU 2022.
Abiraterone-olaparib confers clinical benefit for mCRPC patients
04 Aug 2022
70-gene signature identifies ultra-low risk of distant recurrence in breast cancer patients
MammaPrint, a signature test that includes 70 genes, appears to accurately identify hormone receptor-positive breast cancer (HR+BC) patients who are at ultra-low risk of distant recurrence, reports a recent study.
70-gene signature identifies ultra-low risk of distant recurrence in breast cancer patients
04 Aug 2022
Drinking sugar-sweetened beverages detrimental to gut
People who consume sugar-sweetened beverages, rather than artificially sweetened beverages or natural juices, are at increased risk of developing inflammatory bowel disease, especially Crohn’s disease, as reported in a study.
